{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "19183448", "DateCompleted": {"Year": "2009", "Month": "03", "Day": "24"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "22"}, "Article": {"ArticleDate": [{"Year": "2009", "Month": "01", "Day": "30"}], "Language": ["eng"], "ELocationID": ["10.1186/1471-2407-9-41"], "Journal": {"ISSN": "1471-2407", "JournalIssue": {"Volume": "9", "PubDate": {"Year": "2009", "Month": "Jan", "Day": "30"}}, "Title": "BMC cancer", "ISOAbbreviation": "BMC Cancer"}, "ArticleTitle": "Identification of a potent herbal molecule for the treatment of breast cancer.", "Pagination": {"StartPage": "41", "MedlinePgn": "41"}, "Abstract": {"AbstractText": ["Breast cancer (BCa)-related mortality still remains the second leading cause of cancer-related deaths worldwide. Patients with BCa have increasingly shown resistance and high toxicity to current chemotherapeutic drugs for which identification of novel targeted therapies are required.", "To determine the effect of PDBD on BCa cells, estrogen-receptor positive (ER+)-MCF-7 and estrogen-receptor negative (ER-)-MDA 231 cells were treated with PDBD and the cell viability, apoptotic, cell cycle, Western blot and Promoter assays were performed.", "PDBD inhibits cell viability of ER+ and ER- BCa cells by inducing apoptosis without causing significant toxicity in normal breast epithelial cells. While dissecting the mechanism of action of PDBD on BCa, we found that PDBD inhibits Akt signaling and its downstream targets such as NF-kappaB activation, IAP proteins and Bcl-2 expression. On the other hand, activation of JNK/p38 MAPK-mediated pro-apoptotic signaling was observed in both ER+ and ER- BCa cells.", "These findings suggest that PDBD may have wide therapeutic application in the treatment of BCa."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Sciences, College of Health Sciences, University of Kentucky, Lexington, KY 40536, USA. srinivas.koduru@uky.edu"}], "Identifier": [], "LastName": "Koduru", "ForeName": "Srinivas", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sowmyalakshmi", "ForeName": "Srinivasan", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kumar", "ForeName": "Raj", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Gomathinayagam", "ForeName": "Rohini", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Rohr", "ForeName": "J\u00fcrgen", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Damodaran", "ForeName": "Chendil", "Initials": "C"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Cancer", "NlmUniqueID": "100967800", "ISSNLinking": "1471-2407"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Estrogen"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "metabolism", "physiopathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, Estrogen"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22(16):3302\u20133308. doi: 10.1200/JCO.2004.08.095.", "ArticleIdList": ["10.1200/JCO.2004.08.095", "15310773"]}, {"Citation": "Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 2007;8(2):119\u2013127. doi: 10.1517/14656566.8.2.119.", "ArticleIdList": ["10.1517/14656566.8.2.119", "17257083"]}, {"Citation": "Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857\u2013868. doi: 10.1016/S0092-8674(00)80595-4.", "ArticleIdList": ["10.1016/S0092-8674(00)80595-4", "10102273"]}, {"Citation": "Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785\u2013789. doi: 10.1038/378785a0.", "ArticleIdList": ["10.1038/378785a0", "8524413"]}, {"Citation": "Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol. 1999;19(8):5800\u20135810.", "ArticleIdList": ["PMC84429", "10409766"]}, {"Citation": "Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988\u20131004. doi: 10.1038/nrd1902.", "ArticleIdList": ["10.1038/nrd1902", "16341064"]}, {"Citation": "Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499\u20133511. doi: 10.1101/gad.12.22.3499.", "ArticleIdList": ["10.1101/gad.12.22.3499", "PMC317244", "9832503"]}, {"Citation": "Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3(3):245\u2013252. doi: 10.1038/35060032.", "ArticleIdList": ["10.1038/35060032", "11231573"]}, {"Citation": "Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8(10):1136\u20131144. doi: 10.1038/nm762.", "ArticleIdList": ["10.1038/nm762", "12244303"]}, {"Citation": "Varnai P, Bondeva T, Tamas P, Toth B, Buday L, Hunyady L, Balla T. Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners. J Cell Sci. 2005;118(Pt 20):4879\u20134888. doi: 10.1242/jcs.02606.", "ArticleIdList": ["10.1242/jcs.02606", "16219693"]}, {"Citation": "Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80(2):239\u2013256. doi: 10.1016/S0960-0760(01)00189-3.", "ArticleIdList": ["10.1016/S0960-0760(01)00189-3", "11897507"]}, {"Citation": "Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B, Linder S. ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis. 1999;17(8):649\u2013654. doi: 10.1023/A:1006741228402.", "ArticleIdList": ["10.1023/A:1006741228402", "10919709"]}, {"Citation": "Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5588\u20135597.", "ArticleIdList": ["PMC232407", "9271434"]}, {"Citation": "Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911\u20131912. doi: 10.1126/science.1072682.", "ArticleIdList": ["10.1126/science.1072682", "12471242"]}, {"Citation": "Singh DK, Lippman SM. Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants. Oncology (Williston Park) 1998;12(11):1643\u20131653.", "ArticleIdList": ["9834941"]}, {"Citation": "Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997;57(14):2916\u20132921.", "ArticleIdList": ["9230201"]}, {"Citation": "Goodman GE. The clinical evaluation of cancer prevention agents. Proc Soc Exp Biol Med. 1997;216(2):253\u2013259.", "ArticleIdList": ["9349694"]}, {"Citation": "Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002;4(4):655\u2013663. doi: 10.1089/15230860260220166.", "ArticleIdList": ["10.1089/15230860260220166", "12230878"]}, {"Citation": "Sowmyalakshmi S, Nur EAM, Akbarsha MA, Thirugnanam S, Rohr J, Chendil D. Investigation on Semecarpus Lehyam-a Siddha medicine for breast cancer. Planta. 2005;220(6):910\u2013918. doi: 10.1007/s00425-004-1405-4.", "ArticleIdList": ["10.1007/s00425-004-1405-4", "15517350"]}, {"Citation": "Zhao W, Zhu L, Srinivasan S, Damodaran C, Rohr J. Identification of Urushiols as the Major Active Principle of the Siddha Herbal Medicine Semecarpus Lehyam: Anti-tumor Agents for the treatment of Breast Cancer. Pharmaceutical Biology. in press .", "ArticleIdList": ["PMC2898203", "20617110"]}, {"Citation": "Butler R, Mitchell SH, Tindall DJ, Young CY. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ. 2000;11(1):49\u201361.", "ArticleIdList": ["10672903"]}, {"Citation": "Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004;23(8):1599\u20131607. doi: 10.1038/sj.onc.1207284.", "ArticleIdList": ["10.1038/sj.onc.1207284", "14985701"]}, {"Citation": "Ranga RS, Girija R, Nur-e-Alam M, Sathishkumar S, Akbarsha MA, Thirugnanam S, Rohr J, Ahmed MM, Chendil D. Rasagenthi lehyam (RL) a novel complementary and alternative medicine for prostate cancer. Cancer Chemother Pharmacol. 2004;54(1):7\u201315. doi: 10.1007/s00280-004-0770-9.", "ArticleIdList": ["10.1007/s00280-004-0770-9", "15042313"]}, {"Citation": "Raj Kumar, Sowmyalakshmi Srinivasan, Srinivas Koduru, Pallab Pahari, J\u00fcrgen Rohr, Kyprianou Natasha A, Chendil D. Psoralidin, An Herbal Molecule Inhibits PI3K Mediated Akt Signaling In Androgen Independent Prostate Cancer (AIPC) Cells. Cancer Prevention Research. 2008. in press .", "ArticleIdList": ["PMC2652513", "19223576"]}, {"Citation": "Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene. 2004;23(14):2507\u20132522. doi: 10.1038/sj.onc.1207353.", "ArticleIdList": ["10.1038/sj.onc.1207353", "14676829"]}, {"Citation": "Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007;67(1):246\u2013253. doi: 10.1158/0008-5472.CAN-06-2430.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-2430", "17185378"]}, {"Citation": "El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol. 2003;23(16):5516\u20135525. doi: 10.1128/MCB.23.16.5516-5525.2003.", "ArticleIdList": ["10.1128/MCB.23.16.5516-5525.2003", "PMC166354", "12897127"]}, {"Citation": "Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370. doi: 10.1016/S0092-8674(00)81683-9.", "ArticleIdList": ["10.1016/S0092-8674(00)81683-9", "10647931"]}, {"Citation": "Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, Mische S, Li J, Marcu KB. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem. 2002;277(47):45129\u201345140. doi: 10.1074/jbc.M205165200.", "ArticleIdList": ["10.1074/jbc.M205165200", "PMC1201411", "12221085"]}, {"Citation": "Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47\u201359. doi: 10.1038/nrm2308.", "ArticleIdList": ["10.1038/nrm2308", "18097445"]}, {"Citation": "Yang SR, Cho SD, Ahn NS, Jung JW, Park JS, Jo EH, Hwang JW, Kim SH, Lee BH, Kang KS. The role of p38 MAP kinase and c-Jun N-terminal protein kinase signaling in the differentiation and apoptosis of immortalized neural stem cells. Mutat Res. 2005;579(1\u20132):47\u201357.", "ArticleIdList": ["16046226"]}, {"Citation": "Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990;50(3):717\u2013721.", "ArticleIdList": ["2297709"]}, {"Citation": "Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science. 1990;249(4976):1552\u20131555. doi: 10.1126/science.2218496.", "ArticleIdList": ["10.1126/science.2218496", "2218496"]}, {"Citation": "Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 1992;3(7):401\u2013411.", "ArticleIdList": ["1358180"]}, {"Citation": "Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 2000;19(13):1647\u20131656. doi: 10.1038/sj.onc.1203470.", "ArticleIdList": ["10.1038/sj.onc.1203470", "10763821"]}, {"Citation": "Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812\u2013821. doi: 10.1101/gad.7.5.812.", "ArticleIdList": ["10.1101/gad.7.5.812", "8491378"]}, {"Citation": "Clarke RB. p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res. 2003;5(3):162\u2013163. doi: 10.1186/bcr596.", "ArticleIdList": ["10.1186/bcr596", "PMC165008", "12793899"]}, {"Citation": "Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590\u2013603. doi: 10.1038/sj.leu.2402824.", "ArticleIdList": ["10.1038/sj.leu.2402824", "12646949"]}, {"Citation": "Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer. 2006;118(2):284\u2013289. doi: 10.1002/ijc.21358.", "ArticleIdList": ["10.1002/ijc.21358", "16049961"]}, {"Citation": "Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005;207(2):139\u2013146. doi: 10.1002/path.1829.", "ArticleIdList": ["10.1002/path.1829", "16088978"]}, {"Citation": "Sastre-Garau X, Genin P, Rousseau A, Al Ghuzlan A, Nicolas A, Freneaux P, Rosty C, Sigal-Zafrani B, Couturier J, Thiery JP. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. Histopathology. 2004;45(2):142\u2013147. doi: 10.1111/j.1365-2559.2004.01899.x.", "ArticleIdList": ["10.1111/j.1365-2559.2004.01899.x", "15279632"]}, {"Citation": "Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol. 2004;17(1):15\u201321. doi: 10.1038/modpathol.3800002.", "ArticleIdList": ["10.1038/modpathol.3800002", "14631376"]}, {"Citation": "Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 2006;5(11):2706\u20132715. doi: 10.1158/1535-7163.MCT-06-0352.", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0352", "17121917"]}, {"Citation": "Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031\u20137042. doi: 10.1158/1078-0432.CCR-04-0361.", "ArticleIdList": ["10.1158/1078-0432.CCR-04-0361", "15501983"]}, {"Citation": "Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401(6748):82\u201385. doi: 10.1038/43466.", "ArticleIdList": ["10.1038/43466", "10485710"]}, {"Citation": "Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401(6748):86\u201390. doi: 10.1038/43474.", "ArticleIdList": ["10.1038/43474", "10485711"]}, {"Citation": "Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282(5392):1318\u20131321. doi: 10.1126/science.282.5392.1318.", "ArticleIdList": ["10.1126/science.282.5392.1318", "9812896"]}, {"Citation": "Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17(7):3629\u20133639.", "ArticleIdList": ["PMC232215", "9199297"]}, {"Citation": "Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100(12):2952\u20132960. doi: 10.1172/JCI119848.", "ArticleIdList": ["10.1172/JCI119848", "PMC508506", "9399940"]}, {"Citation": "Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene. 1999;18(16):2567\u20132577. doi: 10.1038/sj.onc.1202599.", "ArticleIdList": ["10.1038/sj.onc.1202599", "10353600"]}, {"Citation": "Hou MF, Lin SB, Yuan SS, Tsai SM, Wu SH, Ou-Yang F, Hsieh JS, Tsai KB, Huang TJ, Tsai LY. The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. Clin Chim Acta. 2003;334(1\u20132):137\u2013144. doi: 10.1016/S0009-8981(03)00196-7.", "ArticleIdList": ["10.1016/S0009-8981(03)00196-7", "12867284"]}, {"Citation": "Heasley LE, Han SY. JNK regulation of oncogenesis. Mol Cells. 2006;21(2):167\u2013173.", "ArticleIdList": ["16682809"]}]}], "History": [{"Year": "2008", "Month": "7", "Day": "16"}, {"Year": "2009", "Month": "1", "Day": "30"}, {"Year": "2009", "Month": "2", "Day": "3", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "2", "Day": "3", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "3", "Day": "25", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "1", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["19183448", "PMC2649156", "10.1186/1471-2407-9-41", "1471-2407-9-41"]}}], "PubmedBookArticle": []}